Pure Global

Prognostic Markers for a Better Follow-up in Head and Neck Cancer. - Trial NCT06094985

Access comprehensive clinical trial information for NCT06094985 through Pure Global AI's free database. This phase not specified trial is sponsored by Karolinska Institutet and is currently Recruiting. The study focuses on Head and Neck Cancer. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06094985
Recruiting
genetic
Trial Details
ClinicalTrials.gov • NCT06094985
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Prognostic Markers for a Better Follow-up in Head and Neck Cancer.

Study Focus

Head and Neck Cancer

DNA exome sequencing of tumor and blood

Observational

genetic

Sponsor & Location

Karolinska Institutet

Stockholm, Sweden

Timeline & Enrollment

N/A

Nov 01, 2023

May 31, 2026

20 participants

Primary Outcome

Recurrence,Survival,Treatment response

Summary

To identify tumor specific DNA mutations and aberrations and to follow these in blood over
 time to predict treatment response/survival and secondly to correlate presence of these
 markers in blood to pathological parameters (LVI, Pn, WPOI and margins), radiological
 findings and to tumor stage.

ICD-10 Classifications

Malignant neoplasm of other and ill-defined sites: Head, face and neck
Malignant neoplasm: Skin of scalp and neck
Malignant neoplasm: Connective and soft tissue of head, face and neck
Carcinoma in situ: Skin of scalp and neck
Secondary and unspecified malignant neoplasm: Lymph nodes of head, face and neck

Data Source

ClinicalTrials.gov

NCT06094985

Non-Device Trial